Document 73 - Assort Design

Document #73 Medical Affairs

Source: url • Audience: medical_affairs • Status: completed

Routing confidence: 90% • Candidates: Medical Affairs, R&D, Commercial

Routing reasons: ML fallback: low confidence (56% < 57%); The document discusses novel nanomedicine research specifically targeting metabolic dysfunction-associated steatohepatitis (MASH), focusing on molecular mechanisms and therapeutic effects.; It presents detailed preclinical experimental data including molecular docking, cell experiments, animal models, and advanced molecular analyses such as RNA sequencing and quantitative phosphorylation proteomics.; The content explores pharmacological intervention (CePA complex) and its effect on biochemical pathways (mTOR signaling), relevant for drug development and clinical translation.; The context and terminology suggest use by medical professionals involved in evaluating new treatments, treatment mechanisms, and safety for liver diseases, typical of a medical affairs audience bridging clinical development and healthcare communication.

Back to Request Back Home

CePA: Novel nanomedicine for alleviating MASH via mTOR repression Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Breastfeeding Cold, Flu & Cough Dermatolog...

Show full document

CePA: Novel nanomedicine for alleviating MASH via mTOR repression Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Breastfeeding Cold, Flu & Cough Dermatology Diabetes Eating Disorders Eye Health Gastrointestinal Health Heart Disease Lung Cancer Mental Health Parkinson's Disease Pregnancy Sleep Urology View Health A-Z × Top Health Categories Coronavirus Disease COVID-19 Eating Disorders Diet & Nutrition Eye Health Artificial Intelligence Gastrointestinal Health Allergies Heart Disease Alzheimer's & Dementia Lung Cancer Arthritis & Rheumatology Mental Health Breast Cancer Parkinson's Disease Breastfeeding Pregnancy Cold, Flu & Cough Sleep Dermatology Urology Diabetes View Health A-Z Medical Home Life Sciences Home About News Life Sciences A-Z White Papers Lab Equipment Interviews Newsletters Webinars More... eBooks Posters Podcasts Contact Meet the Team Advertise Search Become a Member White Papers MediKnowledge eBooks Posters Podcasts Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Webinars eBooks Posters Podcasts Contact Meet the Team Advertise Search Become a Member CePA: Novel nanomedicine for alleviating MASH via mTOR repression Download PDF Copy Reviewed Higher Education Press Jul 16 2024 Metabolic dysfunction-associated steatohepatitis (MASH) is one of the most common chronic liver diseases, primarily caused by metabolic disorders and systemic inflammatory responses. Although the incidence of MASH is gradually increasing, there is a lack of effective drugs and methods for its treatment, thus limiting therapeutic options for MASH. Professor Liu Lei's team has long focused on the treatment and molecular mechanisms of liver-related diseases. Due to cerium's significant antioxidant and anti-inflammatory activities, as well as its hepatophilicity and good biosafety, it shows great potential in liver disease treatment. The researchers first utilized the metal coordination function of the phytic acid (PA) molecule to design and synthesize a cerium-phytic acid (CePA) complex. Compared to PA, the resulting CePA has greater stability and antioxidant activity, providing more stable and effective protection against liver lipid damage. The researchers subsequently validated CePA's high efficiency and safe mTOR inhibition capacity through molecular docking, cell experiments, and MASH animal models, indicating its potentially important role in MASH treatment. Recently, the Liu Lei/Zhao Junlong team from Air Force Medical University and the Qu Yongquan/Tian Zhimin team from Northwestern Polytechnical University published a research paper titled "Phytic acid-based nanomedicine against mTOR represses lipogenesis and immune response for metabolic dysfunction-associated steatohepatitis therapy" in the journal Life Metabolism . The study synthesized a CePA complex by combining PA with cerium ions, which possess phosphodiesterase activity. The research focused on how CePA intervenes in the phosphorylation of mTOR through the occupying effect of phosphate groups and improves inflammatory response and lipid metabolism disorders via the mTOR/AKT regulatory axis. The results showed that CePA significantly alleviated the progression of MASH and fat accumulation in mice fed with a high-sugar, high-fat (HFCFG) diet, demonstrating liver-targeted mTOR inhibition. This provides a valuable research direction for the treatment of MASH and other mTOR-related diseases. The functional changes of CePA on cell metabolic activity and fatty acid oxidation were determined by human primary hepatocytes and mouse normal hepatocytes. The experiments showed that CePA could inhibit lipid metabolism in hepatocytes by blocking phosphorylation and inhibiting the mTOR signaling pathway. Further studies showed that CePA could improve the activation and infiltration of liver macrophages during the occurrence and development of MASH, and CePA could effectively inhibit the phagocytosis of F4/80 labeled macrophages and improve the polarization of macrophages by inhibiting the activation of mTOR. In vivo experiments, the MASH model of an HFCFG diet fed for 16 weeks and the intervention model of an HFCFG diet fed with 1% CePA were established. By measuring the concentrations of alanine transaminase (ALT), aspartate transaminase (AST), and cholesterol (CHO) in mouse serum, it was found that CePA can treat metabolic liver disease and metabolic syndrome more effectively (Figure 2). In addition, through morphological analysis and lipid synthesis and lipid metabolism gene detection, CePA was found to protect HFCFG-induced MASH by regulating lipid droplet accumulation and lipid deposition in liver tissue and liver fibrosis. At the same time, CePA can significantly inhibit the recruitment and infiltration of macrophages induced by HFCFG, and improve the liver inflammatory response during MASH by reducing the M1 polarization of macrophages, suggesting that CePA has a therapeutic effect on MASH, and CePA may exert the above effect by affecting the phosphorylation level of mTOR. Related Stories Global trends shape progress in cell and gene therapies Cellares to expand automated manufacturing to gene-edited stem cell therapies Researchers develop new score to predict the risk of liver cancer Finally, in order to further explore the mechanism by which CePA protects MASH by affecting the phosphorylation of mTOR, the researchers conducted RNA sequencing on liver tissues, and in-depth screening analysis found that CePA could inhibit the mTORC1 signaling pathway (Figure 3). To better verify that CePA can induce molecular changes dependent on inhibition of mTOR phosphorylation level, they performed quantitative phosphorylation proteomic analysis based on mass spectrometry to comprehensively determine phosphorylation and dephosphorylation sites after CePA treatment, and found that the phosphorylation level of mTOR signaling protein decreased after CePA treatment. Overall, the study demonstrated in vitro and in vivo that CePA can spatially block the phosphorylation and activation of mTOR to reduce hepatic steatosis, lipid-related damage, and fibrosis of MASH in vivo and in vitro . Further targeted regulation of various chemical modifications of hepatocytes provides a new idea and an important basis for more accurate and flexible treatment of liver diseases. Source: Higher Education Press Journal reference: Xu, F., et al . (2024). Phytic acid-based nanomedicine against mTOR represses lipogenesis and immune response for metabolic dysfunction-associated steatohepatitis therapy. Life Metabolism . doi.org/10.1093/lifemeta/loae026 . Posted in: Medical Science News | Medical Research News | Medical Condition News Comments (0) Download PDF Copy Suggested Reading Can GLP-1 drugs slow neurodegeneration? New review finds promising signals but limited clinical proof Causal gene mapping identifies key drivers of Alzheimer's disease progression Alzheimer’s plaques decline after CAR-T immune cell treatment in preclinical study Tirzepatide shows dual benefits in sleep apnea trial improving metabolism and reducing inflammation Do cocoa flavanols influence heart and fatty liver risk factors? Optimization of CAR T cells to destroy solid tumors Tahoe Therapeutics generates the largest single-cell atlas ever using INTEGRA Biosciences automated pipetting technologies Dual targeting strategy suppresses pancreatic cancer cell growth Comments The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical. Cancel reply to comment Post a new comment Login (Logout) Quirky Comment Title Post Sign in to keep reading We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free. Sign in with Google Sign in with Apple Sign in with LinkedIn Sign in with Facebook or Sign in with email Trending Stories Latest Interviews Top Health Articles Case report examines potential cancer risks after mRNA vaccination Study uncovers immune trigger behind vaccine-induced immune thrombocytopenia and thrombosis Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation Researchers identify a previously unknown cellular barrier in the brain Ozempic users continue treatment when weight loss works despite side effects Advancing brain microphysiological systems (bMPS) Dr. Lena Smirnova Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. PhD researcher at LifeArc Natasha Bury Targeted protein degradation presents a promising strategy to address antimicrobial resistance, focusing on innovative approaches for gram-negative bacteria. Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research Rosanna Zhang In our latest interview, News-Medical speaks with Rosanna Zhang from ACROBiosystems about utilizing organoids for disease modeling in the field of neuroscience research. Astaxanthin and Human Health: Evidence on Skin, Vision, Brain, and Aging The Gut–Brain–Skin Axis: How Diet and Gut Health Influence Mood, Skin, and Aging How Morning Routines Influence Cognitive Performance, Mood, and Circadian Rhythm Camel Milk Nutrition Facts and Potential Health Benefits Explained Edible Insects as Food: Nutritional Benefits, Safety, and Environmental Impact Latest News Researchers discover a way to breach cancer’s impenetrable fortress Weekend holiday rehabilitation supports recovery in elderly hip fracture patients Novel implant delivers tiny growth-promoting particles directly to injured nerve cells Changes in lymphatic vessels can help identify aggressive oral cancer at an early stage Axol Bioscience acquires ophthalmology business from Newcells Biotech Newsletters you may be interested in Nanomedicine ( Subscribe or Preview ) Cholesterol ( Subscribe or Preview ) Hematology ( Subscribe or Preview ) See all Newsletters » High Credibility: This website adheres to all nine standards of credibility and transparency. Medical Links Medical Home Functional Food News Health A-Z White Papers Thought Leaders Insights MediKnowledge Series Health & Personal Care Medical Devices Drugs eBooks Posters Podcasts Life Sciences Links Life Sciences Home News Lab Instruments & Equipment Life Sciences A-Z White Papers Thought Leaders Insights Webinars eBooks Posters Podcasts Other Useful Links About Meet the Team Search Newsletters Sitemap Advertise Contact Terms & Conditions Privacy & Cookie Policy Content Policy Ownership & Funding Information Other AZoNetwork Sites AZoM AZoNano AZoCleantech AZoOptics AZoRobotics AZoSensors AZoMining AZoQuantum AZoBuild AZoLifeSciences AZoAi Facebook Twitter LinkedIn News-Medical.Net provides this medical information service in accordance with these terms and conditions . Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Update Your Privacy Preferences Last Updated: Wednesday 18 Feb 2026 News-Medical.net - An AZoNetwork Site Owned and operated by AZoNetwork, © 2000-2026 Azthena logo with the word Azthena Maximise chat window Hide chat window Your AI Powered Scientific Assistant Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. To start a conversation, please log into your AZoProfile account first, or create a new account. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content . Log in A few things you need to know before we start. Please read and accept to continue. Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI . Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy . Large Language Models can make mistakes. Consider checking important information. I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements. Please check the box above to proceed. Start Chat Great. Ask your question. Clear Chat Clear Chat Brief Moderate Detailed Azthena may occasionally provide inaccurate responses. Read the full terms . Terms While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information. Read the full Terms & Conditions . Provide Feedback Submit Cancel You might also like... × Obesity drives shared genetic risk behind many chronic disease combinations

One-line Summary

CePA, a cerium-phytic acid nanomedicine, alleviates metabolic dysfunction-associated steatohepatitis (MASH) by repressing mTOR phosphorylation, reducing hepatic lipogenesis, inflammation, and fibrosis in preclinical models.

Decision Bullets

Expected: 3–5 bullets.

Scientific Summary: CePA shows promising hepatoprotective effects via mTOR/AKT axis modulation in vitro and in vivo, with reductions in lipid accumulation, inflammation, and fibrosis.
Evidence Gaps: Clinical translation requires validation of safety, dosing, pharmacokinetics, and long-term efficacy in humans.
Medical Insights: Targeted mTOR repression by nanomedicine offers a novel therapeutic avenue for MASH and other mTOR-related liver diseases.
Stakeholder Considerations: Collaboration among researchers, clinicians, and regulatory bodies is critical to advance CePA from preclinical studies to clinical trials.
Next Steps: Conduct detailed toxicology, dose optimization, and early phase clinical studies to establish CePA’s therapeutic potential and safety profile.

Mind Map

mindmap
  root((CePA Nanomedicine for MASH))
    Mechanism
      mTOR Inhibition
      AKT Signaling Modulation
      Phosphorylation Blockage
    Effects
      Reduced Lipogenesis
      Decreased Inflammation
      Improved Macrophage Polarization
      Reduced Fibrosis
    Preclinical Models
      Cell Studies
      Mouse HFCFG Diet Model
    Research Methods
      Molecular Docking
      RNAseq
      Phosphoproteomics
    Clinical Implications
      Potential MASH Therapy
      Safety and Biosafety
      Need for Clinical Trials
    Stakeholders
      Researchers
      Clinicians
      Regulatory Authorities
      Patients

If needed, use the in-page "View source" button on the job detail page to see the raw mind map.

Key Clues

CePA stabilizes antioxidant activity and targets liver
Represses mTOR phosphorylation and blocks lipogenesis
Modulates macrophage activation and inflammation
Effective in HFCFG diet-induced MASH mouse model
RNAseq and proteomics confirm mTORC1 pathway inhibition

Tag Intelligence

Domain: Clinical & Medical Strategy

Canonical tags

mash
nanomedicine
mtor inhibition
cerium-phytic acid
hepatic steatosis
lipid metabolism
inflammation

View Tag Insights

Tool Summary

Citations: 4

Medical Insights: Targeted mTOR repression by nanomedicine offers a novel therapeutic avenue for MASH and other mTOR-related liver diseases.

eBooks Posters Podcasts Contact Meet the Team Advertise Search Become a Member White Papers MediKnowledge eBooks Posters Podcasts Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Webinars eBooks Posters Podcasts Contact Meet the Team Advertise Search Become a Member CePA: Novel

… Home Life Sciences Home About News Life Sciences A-Z White Papers Lab Equipment Interviews Newsletters Webinars More... eBooks Posters Podcasts Contact Meet the Team Advertise Search Become a Member White Papers MediKnowledge eBooks Posters Podcasts Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Webinars eBooks Posters Podcasts Contact Meet the Team Advertise Search Become a Member CePA: Novel nanomedicine for alleviating MASH via mTOR repression Download PDF Copy Reviewed Higher Education Press Jul 16 2024 Met…

Scientific Summary: CePA shows promising hepatoprotective effects via mTOR/AKT axis modulation in vitro and in vivo, with reductions in lipid accumulation, inflammation, and fibrosis.

The research focused on how CePA intervenes in the phosphorylation of mTOR through the occupying effect of phosphate groups and improves inflammatory response and lipid metabolism disorders via the mTOR/AKT regulatory axis.

…olism . The study synthesized a CePA complex by combining PA with cerium ions, which possess phosphodiesterase activity. The research focused on how CePA intervenes in the phosphorylation of mTOR through the occupying effect of phosphate groups and improves inflammatory response and lipid metabolism disorders via the mTOR/AKT regulatory axis . The results showed that CePA significantly alleviated the progression of MASH and fat accumulation in mice fed with a …

Evidence Gaps: Clinical translation requires validation of safety, dosing, pharmacokinetics, and long-term efficacy in humans.

Astaxanthin and Human Health: Evidence on Skin, Vision, Brain, and Aging The Gut–Brain–Skin Axis: How Diet and Gut Health Influence Mood, Skin, and Aging How Morning Routines Influence Cognitive Performance, Mood, and Circadian Rhythm Camel Milk Nutrition Facts and Potential Health Benefits Explained Edible Insects as

… Rosanna Zhang from ACROBiosystems about utilizing organoids for disease modeling in the field of neuroscience research. Astaxanthin and Human Health: Evidence on Skin, Vision, Brain, and Aging The Gut–Brain–Skin Axis: How Diet and Gut Health Influence Mood, Skin, and Aging How Morning Routines Influence Cognitive Performance, Mood, and Circadian Rhythm Camel Milk Nutrition Facts and Potential Health Benefits Explained Edible Insects as Food: Nutritional Benefits, Safety, and Environmental Impact Latest News Researchers discover a way to breach cancer’s …

Risk flags: 1 High · 0 Medium · 0 Low

High severity risk detected.